MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cance...
Q1 2026
May 15, 2026
FY 2025
Mar 31, 2026
Q4 2025
Q3 2025
Nov 14, 2025
Q2 2025
Aug 14, 2025